Lukas Scheibler

Lukas Scheibler is a declared insider at 2 companies (senior executive); the most frequent names are Apellis Pharmaceuticals, Inc. and Kubota Pharmaceutical Holdings Co Ltd. Between 17 August 2016 and 1 December 2023, the trades on record add up to 62 filings.

In open-market terms, that means 1 purchase worth €51k on one side and 25 sales worth €3.4M on the other. Taken together, the sales exceed the purchases by €3.3M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 14 share grants and 21 option exercises. Since January 2023: no purchases and 2 sales on the market.

Most recently, on 5 December 2023, the filings show an option exercise worth €127k in Apellis Pharmaceuticals, Inc. The most recent open-market purchase was published on 29 May 2018, 3,085 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.